Condition (MeSH)
Ehlers-Danlos Syndrome
ClinicalTrials.gov lists 77 trials for Ehlers-Danlos Syndrome or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
63 of the 77 trials are tagged with Ehlers-Danlos Syndrome itself; the rest are tagged with a narrower condition beneath it.
When did Ehlers-Danlos Syndrome trials start? (20)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 2 trials are registered to start in 2027 or later, and not listed here.
Trials over time, by phase
- Phase 1
- Phase 2
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 9
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 7 |
| 2025 | 5 |
| 2024 | 9 |
| 2023 | 7 |
| 2022 | 9 |
| 2021 | 2 |
| 2020 | 3 |
| 2019 | 3 |
| 2018 | 5 |
| 2017 | 4 |
Showing 10 of 20 earlier years.
Forecast of the full-year count, planned starts included, not rows of this table: about 6 trials starting in 2026 and about 5 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored. The 2026 forecast is below the 7 already registered with a 2026 start date: at the cutoff, 2 trials were already registered to start in October to December, more than the method's monthly average allows for, and the method does not use those planned starts.
Prediction, not a registry value: median of 29 months from start to primary completion across 9 trials still running at the 2026-10-09 snapshot; registered median of 19 months across 33 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Ehlers-Danlos Syndrome trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 1/2 | 1 |
| Phase 2 | 1 |
| Phase 3 | 4 |
| Phase 4 | 3 |
| Not applicable | 29 |
| Observational | 38 |
How many Ehlers-Danlos Syndrome trials are recruiting? (8)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 5 |
| Recruiting | 14 |
| Enrolling by invitation | 1 |
| Active, not recruiting | 6 |
| Completed | 35 |
Showing 5 of 8 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Ehlers-Danlos Syndrome trials? (4)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Integrative Skin Science and Research | 2 |
| National Human Genome Research Institute (NHGRI) | 2 |
| Acer Therapeutics Inc. | 1 |
| Aytu BioPharma, Inc. | 1 |
Which drugs are being tested for Ehlers-Danlos Syndrome? (2)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| DOXY | 1 |
| Increlex | 1 |
Interventions as named in the registry (13)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| 0.9% Chloride Injection Sodium | 2 |
| Lidocaine Hydrochloride Injection 2% | 2 |
| ACER-002 (celiprolol) 200 mg BID | 1 |
| [PRP] platelet rich plasma | 1 |
| Control (placebo) group | 1 |
Showing 5 of 13 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which publications cover Ehlers-Danlos Syndrome? (78)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Exploring fatigue in Marfan and hypermobile Ehlers-Danlos syndromes: an analytical cross-sectional study in two Italian healthcare centres. | BMJ open | 2025 | Yes |
| Efficacy of Irbesartan in Celiprolol-Treated Patients With Vascular Ehlers-Danlos Syndrome. | Circulation | 2025 | Yes |
| Exploring physical activity patterns in adolescents with hypermobility spectrum disorder or hypermobile Ehlers-Danlos Syndrome. | Pediatric rheumatology online journal | 2025 | Yes |
| Proteomic discoveries in hypermobile Ehlers-Danlos syndrome reveal insights into disease pathophysiology. | ImmunoHorizons | 2025 | Yes |
| Autonomic symptom burden, comorbidities and quality of life in women with Hypermobility Spectrum Disorders and hypermobile Ehlers-Danlos syndrome. | Autonomic neuroscience : basic & clinical | 2025 | Yes |
Showing 5 of 78 publications.
Prevalence (6)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Ehlers-Danlos syndrome | Point prevalence | Unknown | Worldwide | Not stated | Exact |
| Ehlers-Danlos syndrome | Point prevalence | Unknown | Worldwide | Not stated | Exact |
| Ehlers-Danlos syndrome | Point prevalence | Unknown | Worldwide | Not stated | Unspecified |
| Ehlers-Danlos syndrome | Prevalence at birth | 1-9 / 1 000 000 | Europe | Not stated | Exact |
| Ehlers-Danlos syndrome | Prevalence at birth | 1-9 / 1 000 000 | Europe | Not stated | Exact |
Showing 5 of 6 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Ehlers-Danlos syndrome | 98249 | Exact | Orphadata Science knowledge files, Product 1 |
| Ehlers-Danlos syndrome | 98249 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials.